Desk edition Search
Amino Wire

Wire

EnforcementSILVER SPRING, Md. · Event December 10, 2024

‘Research use only’ labels did not stop FDA warning letters

FDA looked at product pages, cited studies and social posts to decide what the products were really for.

Plain envelopes, one marked with a red block, beside a rubber stamp
Generated editorial illustration for the Enforcement desk. No real products, people or documents shown.

By

Event date · Published

Reviewed by Amino Wire Editorial Team · Last reviewed

SILVER SPRING, Md. Standards · Corrections

Two warning letters dated December 10, 2024 set out the reasoning FDA has used against “research use only” peptide sellers ever since. One went to Swisschems and one to Summit Research Peptides. Both companies sold GLP-1-class drugs labeled as research chemicals. FDA said those labels did not change what the products were.

What FDA looked at

Swisschems. FDA reviewed swisschems.is in October 2024 and cited the semaglutide product page’s “Peer-Reviewed Studies” section, which listed human trials such as “Once-weekly semaglutide in adults with overweight or obesity.” It also quoted a September 18, 2024 Facebook and Instagram post: “Ready to elevate your research? Semaglutide, a key player in metabolic and weight regulation is now available!… Buy 3 or more and get 10% OFF.” For retatrutide, FDA quoted the description of it as “a promising anti-obesity agent” and the citation of a Phase 2 obesity trial.

Summit Research Peptides. FDA reviewed summitpeptides.shop in October 2024, along with the company’s Facebook page that sent buyers to the store. It listed semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide products.

Both letters apply the same three steps:

  1. Is it a drug? Under FD&C Act section 201(g)(1), yes, if it is intended to treat disease or affect the body’s structure or function.
  2. How is intent shown? By the seller’s own labeling, advertising and statements (21 CFR 201.128). A disclaimer is one piece of evidence. Product pages that describe human weight-loss trials are another, and FDA weighed them more heavily.
  3. Is it a new drug without approval? These products are not “generally recognized as safe and effective” and have no approved application, so selling them across state lines violates sections 301(d) and 505(a).

The Summit letter says it directly: “Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use.”

What followed

FDA used the same reasoning on February 26, 2025 against USApeptide.com, a site listed in Germany, over semaglutide and tirzepatide (status). It used it again in 2026 against Gram Peptides and Prime Sciences in March, and against five sellers in August (report). Our RUO explainer covers the doctrine in more depth.

What changed: key dates

Dated timeline for this report
DateWhat happened
U.S. FDA: Warning letter 695663: Swisschems
U.S. FDA: Warning letter 695607: Summit Research Peptides
Event date for this report
U.S. FDA: Warning letter 696885: USApeptide.com
Amino Wire published this report

Sources

4 linked records
  1. [1] Warning letter 695663: Swisschems U.S. FDA · Primary record
  2. [2] Warning letter 695607: Summit Research Peptides U.S. FDA · Primary record
  3. [3] Warning letter 696885: USApeptide.com U.S. FDA · Primary record
  4. [4] 21 CFR 201.128 — Meaning of 'intended uses' eCFR Primary record

Amino Wire reports regulatory and court records. Nothing here is medical or legal advice, and we do not provide dosing information. Named companies may respond; see right of reply.

More from the wire

All news